Zylox-Tonbridge Medical Technology Co., Ltd. executed an on-market repurchase of 59,000 H shares on 8 July 2026.

• Pricing and consideration: The shares were bought back on the Hong Kong Stock Exchange at prices between HKD 19.04 and HKD 19.43, for a total consideration of HKD 1.13 million (volume-weighted average price: HKD 19.22).

• Impact on share capital: – Issued shares excluding treasury stock fell 0.0178 % to 323.84 million. – Treasury shares increased to 12.51 million. – Total issued shares remained unchanged at 336.35 million.

• Mandate utilisation: The repurchase was made under the mandate approved on 13 May 2026, which allows up to 32.72 million shares to be bought back. Cumulative purchases under this authority now total 3.36 million shares, representing 1.00 % of the company’s issued shares on the mandate date.

• Post-repurchase restrictions: In line with Hong Kong listing rules, Zylox-Tonbridge may not issue new shares or dispose of treasury shares until 7 August 2026.

The board confirmed that the transaction complied with all applicable listing rules and regulatory requirements, and all related funds have been fully settled.